A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 855-859

  Hussain, S A ^a   Palmer, D H ^a   Lloyd, B ^a   Collins, S I ^b   Barton, D ^b   Ansari, J ^c   James, N D ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Bladder cancer; Gemcitabine; Neo adjuvant chemotherapy; Split dose cisplatin outpatient chemotherapy

Indexed keywords

CISPLATIN; GEMCITABINE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CYSTECTOMY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOCYTOSCOPY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE CANCER; MUSCLE INVASIVE BLADDER CANCER; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIC SEPSIS; OUTCOME ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA OF THE BLADDER; TREATMENT RESPONSE;

EID: 84856833529     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.563     Document Type: Article

References (22)

1. Montie JE, Smith DC and Sandler HM: Carcinoma of the bladder. In: Clinical Oncology. Abbeloff MD (ed). Churchill Livingstone Publications, London, pp 1800-1818, 2000.
2. Messing EM, Young TB, Hunt VB, et al: Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentation. Urology 45: 387-396, 1995.
3. Whitmore WF: Management of invasive bladder neoplasms. Semin Urol 1: 4-10, 1983.
4. Freiha F, Reese J and Torti FM: A randomised trial of radical cystectomy versus radical cystectomy plus Cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155: 495-499, 1996.
5. International Collaboration of Trialists: Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer: a randomised controlled trial. Lancet 354: 533-540, 1999.
6. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S and Hannisdal E: Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155: 1903-1906, 1996.
7. Stockle M, Wellek S, Meyenburg W, et al: Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48: 868-875, 1996.
8. Sternberg CN and Calabrò F: Neo-adjuvant chemotherapy in invasive bladder cancer. World J Urol 19: 94-98, 2001.
9. Grossman, HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859-866, 2003.
10. Griffiths G, Hall R, Sylvester R, Raghavan D and Parmar MK: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29: 2171-2177, 2011.
11. Juffs HG, Moore MJ and Tannock IF: The role of systemic chemotherapy in the management of muscle - invasive bladder cancer. Lancet Oncol 3: 738-747, 2002.
12. Sternberg C, Marini L and Calabrò F: Systemic chemotherapy of bladder cancer. In: Bladder Cancer: Biology and Management. Skinner DG and Syrigos KN (eds). Oxford University Press, New York, pp 299-315, 1999.
13. Von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomised, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077, 2000.
14. de Wit R, Bochner BH and Scher HI: Treatment for metastatic urothelial cancer. In: American Society of Clinical Oncology educational book. Perry CM (ed). pp 226-244, 2001.
15. Hussain SA and James ND: The role of systemic chemotherapy in advanced and metastatic bladder cancer. Lancet Oncol 4: 489-497, 2003.
16. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 2: 521-530, 1996.
17. Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH and Schellens JH: DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 65: 275-282, 2003.
18. Hussain SA, Stocken DD, Riley P, et al: A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 91: 844-849, 2004.
19. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Statist Association 53: 457-458, 1958.
20. Lippe P, Tummarello D, Monterubbianesi MC, et al: Weekly gemcitabine and cisplatin in advanced non small cell lung cancer: A phase II study. Ann Oncol 10: 217-221, 1999.
21. Berardi R, Porfiri E, Scartozzi M, et al: Elderly patients with advanced non small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine. Oncology 65: 198-203, 2003.
22. Bochner BH: Chemotherapy: standardizing the care of invasive bladder cancer. Nat Rev Clin Oncol 8: 454-455, 2011.